Rigel Announces Offering of 5,000,000 Shares of Common Stock
2007-04-30 06:00 (New York)
SOUTH SAN FRANCISCO, April 30 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will initiate an
offering of 5,000,000 shares of common stock under an existing shelf
registration statement. It is currently anticipated that the underwriters will
be granted an over-allotment option for an additional 750,000 shares.
Credit Suisse Securities (USA) LLC and Lehman Brothers Inc. will be acting
as joint book-runners of the offering, with Thomas Weisel Partners LLC acting
as co-manager.
A preliminary prospectus supplement relating to these securities will be
filed with the Securities and Exchange Commission but remains subject to
completion. These securities may not be sold, nor may offers to buy be
accepted, prior to the time that the prospectus supplement and related
prospectus are delivered in final form. This press release does not constitute
an offer to sell or the solicitation of an offer to buy any of the securities.
Copies of the preliminary prospectus supplement and related prospectus
relating to the offering may be obtained from Credit Suisse Securities (USA)
LLC, Prospectus Department, One Madison Avenue, New York, New York 10010-3629
(Telephone number 1-800-221-1037) and Lehman Brothers Inc., c/o Broadridge
Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717.
About Rigel (www.rigel.com)
We are a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of
inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to
file one new investigative new drug application in a significant indication
each year. We have achieved this goal each year beginning in 2002. Our
pioneering research focuses on intracellular signaling pathways and related
targets that are critical to disease mechanisms. Our productivity has resulted
in strategic collaborations with large pharmaceutical partners to develop and
market our product candidates. We have internal product development programs
in inflammatory/autoimmune diseases, such as rheumatoid arthritis and
thrombocytopenia, and cancer, as well as partnered product development
programs relating to asthma and cancer. |
